HUMA

$0.41-12.47%visit website

Humacyte, Inc.

Market Cap

$114M

Live price × SEC shares (Aug 10, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.49

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

53.9

TTM to Jun 2026 · revenue

P/B

3.7

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

N/M

TTM to Jun 2026 · negative EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	753	467	495	406	2,121
Cost of revenue	260	9,082	2,038	1,231	12,611
Research & development	17,273	14,605	19,462	18,144	69,484
Selling, general & administrative	7,610
Operating income	(24,390)	(30,836)	(28,935)	(26,996)	(111,157)
Interest expense	2,612	3,093	2,271	2,321	10,297
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(17,510)	(24,804)	(17,619)	(36,802)	(96,735)
EPS (basic) ($)	(0.11)		(0.09)	(0.16)	—
EPS (diluted) ($)	(0.11)		(0.09)	(0.16)	—
Weighted avg. shares (basic)	158,313		197,847	234,182
Weighted avg. shares (diluted)	158,313		197,847	234,182

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 12, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 20 more quarters, back to Q3 FY2020, with Tormere Pro.

Signals

purchases / sales, 90d

Short Volume

75%

W/W +26.8pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

4.81x

Avg Daily Buying (90d)

556 sh/day

Baseline Daily Buying

277 sh/day

Unique Buyers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-14	2026-09-15	Jones Keith Anthony	Director	Purchase	10.0K	$0.56	$6K	50.0K	View
2026-08-20	2026-08-21	Jones Keith Anthony	Director	Purchase	10.0K	$0.69	$7K	40.0K	View
2026-08-17	2026-08-19	Jones Keith Anthony	Director	Purchase	30.0K	$0.59	$18K	30.0K	View
2026-05-19	2026-05-20	Sebelius Kathleen	Director	Purchase	56.8K	$0.88	$50K	148.0K	View
2026-05-18	2026-05-20	Parikh Shamik J	Chief Medical Officer	Sale	45.9K	$0.90	$41K	272.7K	View

1–5 of 7

1 / 2

Recent News

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Yahoo · 2026-10-30

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

Yahoo · 2026-10-28

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

Yahoo · 2026-10-23

Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026

Benzinga · 2026-10-23

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Yahoo · 2026-10-21

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Yahoo · 2026-10-19

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga · 2026-10-16

12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga · 2026-10-15

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Yahoo · 2026-10-15

Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026

Benzinga · 2026-10-15

49 hospitals ordered a bioengineered blood vessel. Several surgeons submitted patient case studies for presentations.

Stock Titan · 2026-10-15

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Yahoo · 2026-10-13

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Yahoo · 2026-10-12

A trial compares two blood-vessel options for women on dialysis. Interim results will be presented Oct. 22.

Stock Titan · 2026-10-12

$HUMA stock is down 11% today. Here's what we see in our data.

Quiver Quantitative · 2026-10-09

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-09-14	Jones Keith Anthony	P	10,000	$5,620
2026-08-20	Jones Keith Anthony	P	10,000	$6,930
2026-08-17	Jones Keith Anthony	P	30,000	$17,820
2026-05-19	Sebelius Kathleen	P	56,818	$49,999.84
2026-05-18	Parikh Shamik J	S	45,887	$41,146.87

HUMA

Financial Statements

Signals

Factor Profile

Recent News

Humacyte, Inc. (HUMA)

Reporting Insiders

Factor Profile